News & Events

14.05.2012

DYCONEX demonstrates 20-μm line & space capability on multilayer LCP product

DYCONEX has reached yet another significant milestone in its quest to bring cutting-edge technology to the marketplace: ultra-high density LCP substrates!
14.05.2012

DYCONEX is rated as a No.1 company by Dun & Bradstreet

Dun & Bradstreet is one of the world's most respected sources of business information, enabling companies to make commercial decisions with a high level of confidence. We are pleased to announce that in March 2012, DYCONEX AG was awarded a No.1 rating by Dun & Bradstreet for our financial strength, creditworthiness and minimum risk of failure.
05.04.2012

DYCONEX is a founding member of iNEMI’s «Defining Reliability Requirements for Implantable Medical Devices» project

We are proud to announce that DYCONEX is a founding member of a project being set up by the International Electronics Manufacturing Initiative (iNEMI) entitled «Defining Reliability Requirements for Implantable Medical Devices.»

DYCONEX at SPIE 2012

SPIE
Defense, Security + Sensing
April 24 - 26, 2012
Baltimore Convention Center, Baltimore, MD, USA
Booth# 314

DYCONEX at SMT 2012

SMT

SMT/HYBRID/PACKAGING
May 8 - 10, 2012
Messezentrum Nürnberg, Germany
DYCONEX: Hall 9, Booth#428

DYCONEX LIQUID CRYSTAL POLYMER (LCP) SUBSTRATE PROVES CYTOTOXICITY CONFORMITY ACCORDING TO ISO 10993-5

Cytotoxicity, a standardized test for materials used in medical devices, is used to determine if significant quantities of harmful extractable substances are present and how these may negatively affect cellular components. Harlan Cytotest Cell Research GmbH recently performed a cytotoxicity test on an LCP product manufactured by DYCONEX and certified in an official declaration the non-cytotoxicity of the product and it's suitability for in-vitro application.

Due to its biocompatibility, hermeticity properties, chemical inertness and advantageous electromechanical properties, LCP circuit boards are especially well-suited for biomedical and temporary implantable applications.